Evaluation of the Effectiveness of Direct-Acting Antiviral Agents in Patients With Hepatitis C
KLIMIK JOURNAL, vol.33, no.3, pp.297-306, 2020 (ESCI, Scopus)
- Publication Type: Article / Article
- Volume: 33 Issue: 3
- Publication Date: 2020
- Doi Number: 10.5152/kd.2020.60
- Journal Name: KLIMIK JOURNAL
- Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database
- Page Numbers: pp.297-306
- Keywords: Hepatitis C, sofosbuvir, ledipasvir, ombitasvir, paritaprevir, dasabuvir, VIRUS GENOTYPE 1, 4 INFECTION, RIBAVIRIN, EFFICACY, LEDIPASVIR/SOFOSBUVIR, SOFOSBUVIR, SAFETY
- Open Archive Collection: AVESIS Open Access Collection
- Ondokuz Mayıs University Affiliated: Yes
Abstract
Objective: Hepatitis C virus (HCV) infection is a global problem with personal, social and economic impacts. Approximately 85% of patients infected with HCV cannot achieve virus clearance. Cirrhosis, hepatocellular carcinoma and death may develop in patients with chronic infection.Until recently, treatments for chronic hepatitis C were difficult to use with many side effects, low treatment responses, and relapses. Direct-acting antivirals (DAAs) prevent HCV replication, and thir effectiveness is over 90%. In this study, we aimed to evaluate the achievement of these treatments.